Table 1.
Patients characteristics of group 1 (prostate volume ≤ 30 mL) and group 2 (prostate volume > 30 mL).
| Characteristics | Pre-propensity score matching | Post- propensity score matching | ||||
|---|---|---|---|---|---|---|
| Group 1 | Group 2 | p-value | Group 1 | Group 2 | p-value | |
| 248 | 108 | 107 | 107 | |||
| Age (median, IQR) | 62.0 (53.5–71.0) | 69.0 (62.0–76.0) | < 0.001 | 65.0 (57.0–74.0) | 68.0 (62.0–76.0) | 0.128 |
| BMI (median, IQR) | 23.7 (21.7–25.8) | 24.3 (22.4–26.6) | 0.011 | 24.2 (21.9–26.2) | 24.2 (22.4–26.4) | 0.242 |
| Smoking | 0.270 | 0.550 | ||||
| Non-smoker | 64 (25.8%) | 34 (31.5%) | 30 (28.0%) | 34 (31.8%) | ||
| Current or former smoker | 184 (74.2%) | 74 (68.5%) | 77 (72.0%) | 73 (68.2%) | ||
| Tumor size (median, IQR) | 1.5 (1.0–2.3) | 1.8 (1.0–2.8) | 0.039 | 1.6 (1.1–2.5) | 1.8 (1.0–2.8) | 0.736 |
| Multifocal tumor | 119 (48.0%) | 52 (48.1%) | 0.977 | 55 (51.4%) | 52 (48.1%) | 0.682 |
| Tumor grade | 0.020 | 0.020 | ||||
| Low grade | 132 (53.2%) | 43 (39.8%) | 51 (47.7%) | 43 (40.2%) | ||
| High grade | 116 (46.8%) | 65 (60.2%) | 56 (52.3%) | 64 (59.8%) | ||
| Pathologic T stage | 0.027 | 0.122 | ||||
| pTa | 40 (16.1%) | 8 (7.4%) | 15 (14.0%) | 8 (7.5%) | ||
| pT1 | 208 (83.9%) | 100 (92.6%) | 92 (86.0%) | 99 (92.5%) | ||
| Tumor variant | 14 (5.6%) | 10 (9.3%) | 0.211 | 9 (8.4%) | 10 (9.3%) | 0.810 |
| CIS | 10 (4.0%) | 4 (3.7%) | 0.883 | 3 (2.8%) | 4 (3.7%) | > 0.999 |
| Immediate intravesical therapy | 26 (10.5%) | 9 (8.3%) | 0.531 | 8 (7.5%) | 9 (8.4%) | 0.800 |
| Adjuvant intravesical therapy | 0.201 | 0.537 | ||||
| No | 138 (55.6%) | 49 (45.4%) | 55 (51.4%) | 48 (44.9%) | ||
| Chemotherapy | 36 (14.5%) | 20 (18.5%) | 37 (34.6%) | 39 (36.4%) | ||
| BCG | 74 (29.8%) | 39 (36.1%) | 15 (14.0%) | 20 (18.7%) | ||
IQR interquartile range, BMI body mass index, CIS carcinoma in situ, BCG bacillus Calmette–Guérin.